Cite
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
MLA
Morrison, Austin R., et al. “Clinical Characteristics and Predictors of Survival in Adults with Coronavirus Disease 2019 Receiving Tocilizumab.” Journal of Autoimmunity, vol. 114, Nov. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.jaut.2020.102512.
APA
Morrison, A. R., Johnson, J. M., Griebe, K. M., Jones, M. C., Stine, J. J., Hencken, L. N., To, L., Bianchini, M. L., Vahia, A. T., Swiderek, J., Ramesh, M. S., Peters, M. A., & Smith, Z. R. (2020). Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Journal of Autoimmunity, 114, N.PAG. https://doi.org/10.1016/j.jaut.2020.102512
Chicago
Morrison, Austin R., Joseph M. Johnson, Kristin M. Griebe, Mathew C. Jones, John J. Stine, Laura N. Hencken, Long To, et al. 2020. “Clinical Characteristics and Predictors of Survival in Adults with Coronavirus Disease 2019 Receiving Tocilizumab.” Journal of Autoimmunity 114 (November): N.PAG. doi:10.1016/j.jaut.2020.102512.